tbuckley/cabot-search huggingface dataset:
P3.02c-084 Predictive and Prognostic Clinical and Pathological Factors of Nivolumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Patients
Authors: Paloma Martin, María De Julián, Javier Perez Altozano, Carmen Salvador Coloma, José García Sánchez, Amelia Insa Molla, María Martín, Xabier Mielgo Rubio, Sara Marin, Ana Blasco Cordellat, Sara Blasco Cordellat, Regina Gironés, Diego Marquez, Francisco Aparisi, Maica Bas Cerda, Óscar Juan, Javier Garde-Noguera
Journal: Journal of Thoracic Oncology (2017)
Clonal Analysis of SF3B1, JAK2 and MPL in Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis
Authors: Ilaria Ambaglio, Anna Gallì, Daniela Pietra, Matteo G Della Porta, Marta Ubezio, Matteo C Da Vià, Elisa Bono, Chiara Milanesi, Erica Travaglino, Rosangela Invernizzi, Elli Papaemmanuil, Peter Campbell, Luca Malcovati, Mario Cazzola
Journal: Blood (2012)
2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults With Aortic Stenosis
Authors: Catherine M. Otto, Dharam J. Kumbhani, Karen P. Alexander, John H. Calhoon, Milind Y. Desai, Sanjay Kaul, James C. Lee, Carlos E. Ruiz, Christina M. Vassileva
Journal: Journal of the American College of Cardiology (2017)
Correction: Noncanonical WNT-5A signaling impairs endogenous lung repair in COPD
Authors: Hoeke A. Baarsma, Wioletta Skronska-Wasek, Kathrin Mutze, Florian Ciolek, Darcy E. Wagner, Gerrit John-Schuster, Katharina Heinzelmann, Andreas Günther, Ken R. Bracke, Maylis Dagouassat, Jorge Boczkowski, Guy G. Brusselle, Ron Smits, Oliver Eickelberg, Ali Ö. Yildirim, Melanie Königshoff
Journal: The Journal of Experimental Medicine (2017)

Vol. 214, No. 1, January 2017. Pages [143–163][1].

The authors regret that in their original paper, the left two micrographs in Fig. 7 C appeared as duplicates. The corrected figure appears below. The online HTML and PDF versions of this article have been corrected. The error only remains in the
MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
Authors: Alex Drilon, Sai-Hong Ou, Jeffrey Clark, D. Ross Camidge, Mark Socinski, Jared Weiss, Benjamin Solomon, Gregory Riely, Rebecca Heist, Geoffrey Shapiro, Sherry Wang, Maria Winter, Katherine Monti, Keith Wilner, Paul Paik
Journal: Journal of Thoracic Oncology (2017)
KLF4 and YY1 Are Resistant Factors in NHL and Potential Therapeutic Targets: The New Resistant NF-κb/YY1/KLF4/BclxL/Mcl-1 Axis
Authors: Mayra R Montecillo-Aguado, Gabriel G Vega, Hector Mayani, Sara Huerta-Yepez, Benjamin Bonavida, Otoniel Martinez-Maza, Mario I. Vega
Journal: Blood (2015)
Immune gene polymorphisms predict overall survival for stage IV melanoma patients treated with biochemotherapy
Authors: D. Liu, S. J. O'Day, D. Yang, P. Boasberg, R. Milford, T. Kristedja, S. Groshen, J. S. Weber
Journal: Journal of Clinical Oncology (2004)

7550 Background: Although high response rates have been shown using biochemotherapy regimens for stage IV melanoma, median survival is less than one year and the regimen is not clearly superior to chemotherapy alone. We hypothesized that single nucleotide polymorphisms (SNPs) may impact on the clinical outcome for patients treated with biochemotherapy and predict those likely to benefit from this therapy. The present study focused on immune-associated polymorphisms. Methods: SNP of immune genes (IFN-γ promoter +874, IL-10 -1082, and IL-8 -521) were analyzed by PCR-RFLP and ARMS-PCR from 90 patients with Stage IV melanoma treated with a biochemotherapy regimen (Cisplatinum, Vinblastine, Dacarbazine, IL-2 and IFN-α either with or without Tamoxifen). Results: Univariate analysis showed that the IFN-γ +874 T/T genotype (correlated with high baseline IFN-γ production) was significantly associated with poor overall survival (p<0.001), while the IL-10 SNP -1082 G/G (correlated with high baseline IL-10 production) and the IL-8 -251 A/T, T/T SNPs (correlated with low baseline IL-8 production) were marginally associated with poor overall survival (p=0.065 and 0.045 respectively). By combining the three genetic polymorphisms, patients were classified into four distinct subgroups based on the number of unfavorable SNPs. Those with more unfavorable polymorphisms exhibited significant lower survival (3 unfavorable SNPs with 180-day median survival < 2 unfavorable polymorphisms with 330-day median survival < 1 unfavorable polymorphism with 346-day median survival < 0 unfavorable polymorphism with 808-day median survival) (p<0.0001). Conclusions: Individual immune SNPs predicted clinical outcome for advanced melanoma patients who received biochemotherapy, and might be useful to select patients more likely to benefit from this treatment. The combined effects of immune-associated polymorphisms and those encoding DNA repair genes (Liu et al, 2003 submitted) may impact on the outcome of biochemotherapy and allow selection of appropriate candidates for this therapy. No significant financial relationships to disclose.
OA04.07 Clinical Characteristics of Lung Adenocarcinoma in the Young: Results from the Genomics of Young Lung Cancer Study
Authors: Barbara Gitlitz, Anna Wu, Marisa Bittoni, Bonnie Addario, Alicia Sable-Hunt, Mark Jennings, Silvia Novello, Tiziana Vavala, Ruthia Chen, Deborah Morosini, Geoffrey Oxnard, S. Lani Park
Journal: Journal of Thoracic Oncology (2017)
Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study
Authors: David Montani, Barbara Girerd, Xavier Jaïs, Marilyne Levy, David Amar, Laurent Savale, Peter Dorfmüller, Andrei Seferian, Edmund M Lau, Mélanie Eyries, Jérôme Le Pavec, Florence Parent, Damien Bonnet, Florent Soubrier, Elie Fadel, Olivier Sitbon, Gérald Simonneau, Marc Humbert
Journal: The Lancet Respiratory Medicine (2017)
A phase I clinical trial of a genetically modified and imageable oncolytic vaccinia virus GL-ONC1 with clinical green fluorescent protein (GFP) imaging.
Authors: J. V. Pedersen, E. M. Karapanagiotou, A. Biondo, N. Tunariu, M. Puglisi, K. A. Denholm, S. Sassi, D. Mansfield, T. A. Yap, J. S. De Bono, K. J. Harrington
Journal: Journal of Clinical Oncology (2011)

2577 Background: GL-ONC1 is a genetically engineered vaccinia virus attenuated by insertion of the ruc-gfp (Renilla luciferase and Aequorea green fluorescent protein fusion gene), beta-galactosidase (lacZ) and beta-glucuronidase (gusA) reporter genes into the F14.5L, J2R (thymidine kinase) and A56R (hemagglutinin) loci, respectively. A Phase I trial of intravenous GL-ONC1 was pursued to evaluate safety, tolerability, tumour delivery, neutralizing antibody development and anti tumour activity. Methods: GL-ONC1 was to be administered at escalating doses (1×105, 1×106, 1×107, 1×108, 1×109, 3×109 plaque-forming units (pfu) on day 1 only; 1.667×107 and 1.667×108 pfu on day 1-3; 1×109 pfu on day 1-5) using a 3+3 dose escalation design and a q28 days schedule. GFP imaging was performed at baseline and after each cycle on superficial and mucosal lesions. Results: To date, 21 patients (males 15, median age 57 years) have been treated without dose limiting toxicities. Adverse events reported were generally mild (grade 1/2) and included pyrexia (n:8), fatigue (n:4), myalgia (n:3), pustular rash (n:2), hypotension (n:2), nausea (n:2), tachycardia (n:2), anorexia (n:1), diarrhoea (n:1), hyperhidrosis (n:1), oedema (n:1), rhinorrhea (n:1), rigor (n:1), seborrhoea (n:1), thrombocytosis (n:1), flank pain (n:1), feet plantar tenderness (n:1), back pain (n:1) calf pain (n:1) and vomiting (n:1). One patient suffered a left common femoral artery embolism of uncertain causality (grade 3). Two patients had a pustular rash, 1 asymptomatic (grade 1) and 1 symptomatic with itching (grade 2). Both appeared during the first week of treatment with green fluorescence on GFP imaging and positivity by viral plaque assay (VPA) and resolved spontaneously by the end of cycle 1. VPA of blood, urine, stool and sputum were negative for viral shedding in all but 1 patient who had positive shedding for 11 days. Increased neutralizing antibody titres were seen in all tested patients except 1. Best response was RECIST stable disease > 6 months (n:1) and 3-6 months (n:5). Conclusions: GL-ONC1 can be administered intravenously, is well tolerated and its delivery can be imaged in cancer patients.
P259 Cost analysis of implementing a pe pathway incorporating 3-level wells scoring, perc rules and age-adjusted d-dimers
Authors: A Mahmood, C Durrans, S Naik, M Anwar
Journal: Thorax (2016)

<h3>Background</h3> Acute pulmonary embolism (PE) is a common presentation. Currently NICE recommends 2-level Well scoring, which may over-investigate patients leading to unnecessary anti-coagulation and contrast-related risks and significant financial costs. We investigated whether further risk stratification using a combination of 3-level Wells scoring, PERC rules and age-adjusted D-dimers could minimise costs and enhance patient safety. <h3>Methods</h3> Retrospective analysis of patients who underwent CTPA and had complete data between September 2014 and August 2015 was carried out. Wells scores, PERC scores and age-adjusted D-dimers were calculated and compared against CTPA findings. <h3>Results</h3> Out of 1174 patients who underwent CTPA, 1158 had complete data set. Application of PERC rules to low-risk patients (Wells score 0–1; n = 311, 27%) would have avoided 64 CTPAs, but missed 3 PEs, with a 95% sensitivity (95% CI: 0.85–0.97), 24% specificity (95% CI: 0.19–0.30), and avoided 56 D-dimers. For intermediate-risk patients (Wells score 2−7), age-adjusted D-dimers would have avoided 265 CTPAs but missed 32 PEs, with an 81% sensitivity (95% CI: 0.74–0.86), 50% specificity (95% CI: 0.45–0.55). High-risk patients should proceed directly to CTPA. The combination of 3-level Wells scoring, PERC rules, and age-adjusted D-dimers would have avoided 450 CTPAs (39%) but missed 39 PEs (8%), with an estimated financial saving of at least £255,150 (local CTPA tariff £567). Non-age adjusted D-dimers would have reduced this avoiding 132 CTPAs (11%), and missing only 7 PEs (5%). Further saving would have resulted from avoiding D-dimer testing in low risk PERC negative patients, and high risk patients. <h3>Conclusion</h3> The use of a PE algorithm incorporating multiple clinical assessment tools results in a pathway which can help rationalise the number of CTPAs performed and D-dimers requested, without significantly increasing the proportion of missed PEs. <h3>References</h3> Forciea MA, <i>et al</i>. Evaluation of patients with suspected acute pulmonary embolism: best practice advice from the clinical guidelines committee of the American College of Physicians. <i>Ann Intern Med</i> 2015;<b>163</b>(9):701–11. Singh B, <i>et al</i>. Pulmonary embolism rule-out criteria (PERC) in pulmonary embolism–revisited: a systematic review and meta-analysis. <i>Emerg Med J</i> 2013;<b>30</b>(9):701–6.
OA08.01 Exploration of the Underlying Mechanisms of Leptomeningeal Metastasis in NSCLC Patients through NGS of Cerebrospinal Fluid
Authors: Yun Fan, Min Hu, Xuehua Zhu, Mengzhao Wang, Yanjun Xu, Xuesong Lv, Haiyan Xu, Jingyan Ding, Xin Ye, Luo Fang, Zhiyu Huang, Lulu Miao, Lei Gong, Weimin Mao, Hongyang Lu
Journal: Journal of Thoracic Oncology (2017)
P1.02-084 Polo-Like Kinase 1 (PLK1) Inhibition Decreases Mutational Activity in Bronchial Epithelial Cells Exposed to Tobacco Carcinogens
Authors: Daniel Merrick, Elizabeth Donald, Jessica Malloy, David Astling, Wilbur Franklin, Dara Aisner, Kristy Crooks, Michael Seager, Jerry Haney, Robert Keith, Lori Dwyer-Nield, Meredith Tennis, Kenneth Jones
Journal: Journal of Thoracic Oncology (2017)
Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease
Authors: Anna Hadjihambi, Francesco De Chiara, Patrick S. Hosford, Abeba Habtetion, Anastassios Karagiannis, Nathan Davies, Alexander V. Gourine, Rajiv Jalan
Journal: Hepatology (2017)

The pathogenesis of hepatic encephalopathy (HE) in cirrhosis is multifactorial and ammonia is thought to play a key role. Astroglial dysfunction is known to be present in HE. Astrocytes are extensively connected by gap junctions formed of connexins, which also exist as functional hemichannels allowing exchange of molecules between the cytoplasm and the extracellular milieu. The astrocyte‐neuron lactate shuttle hypothesis suggests that neuronal activity is fueled (at least in part) by lactate provided by neighboring astrocytes. We hypothesized that in HE, astroglial dysfunction could impair metabolic communication between astrocytes and neurons. In this study, we determined whether hyperammonemia leads to hemichannel dysfunction and impairs lactate transport in the cerebral cortex using rat models of HE (bile duct ligation [BDL] and induced hyperammonemia) and also evaluated the effect of ammonia‐lowering treatment (ornithine phenylacetate [OP]). Plasma ammonia concentration in BDL rats was significantly reduced by OP treatment. Biosensor recordings demonstrated that HE is associated with a significant reduction in both tonic and hypoxia‐induced lactate release in the cerebral cortex, which was normalized by OP treatment. Cortical dye loading experiments revealed hemichannel dysfunction in HE with improvement following OP treatment, while the expression of key connexins was unaffected. Conclusion : The results of the present study demonstrate that HE is associated with central nervous system hemichannel dysfunction, with ammonia playing a key role. The data provide evidence of a potential neuronal energy deficit due to impaired hemichannel‐mediated lactate transport between astrocytes and neurons as a possible mechanism underlying pathogenesis of HE. (H epatology 2017;65:1306‐1318)
DNA Methyltransferase 3B (DNMT3B) Protein Expression Predicts Survival in Patients with Acute Myeloid Leukemia (AML)
Authors: Tim Sauer, Christina Drusio, Irawan Wisudanto, Kim Friedel, Petra Tschanter, Nils H. Thoennissen, Cristina Sauerland, Gabriele Köhler, Thomas Büchner, Wolfgang E. Berdel, Utz Krug, Carsten Müller-Tidow
Journal: Blood (2012)
Focal Lesion (FL) Identification by MRI and Metastatic Bone Survey (MBS) in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2 (TT2).
Authors: Ronald Walker, Jeffrey Haessler, Guido Tricot, John D. Shaughnessy, Joshua Epstein, Jeffrey Sawyer, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Mauricio Pineda-Roman, Klaus Hollmig, John Crowley, Bart Barlogie
Journal: Blood (2006)
Inducible Caspase 9 as a Safety Switch in Genetically Modified Cytotoxic T Cells.
Authors: Karin C. Straathof, Martin A. Pule, Patricia Yotnda, Gianpietro Dotti, Elio F. Vanin, Malcolm K. Brenner, Helen E. Heslop, David M. Spencer, Cliona M. Rooney
Journal: Blood (2004)
MA17.07 Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer
Authors: Aadel Chaudhuri, Alexander Lovejoy, Jacob Chabon, Aaron Newman, Henning Stehr, Carmen Say, Justin Carter, Li Zhou, Robert West, Joseph Shrager, Joel Neal, Heather Wakelee, Billy Loo, Ash Alizadeh, Maximilian Diehn
Journal: Journal of Thoracic Oncology (2017)
STAT5 and NF-κB Induced Oncogenic Mir-155 Directly Targets PU.1 in FLT3-ITD Associated AML
Authors: Dennis Gerloff, Rebekka Grundler, Daniela Braeuer-Hartmann, Christiane Katzerke, Jens-Uwe Hartmann, Carsten Mueller-Tidow, Justus Duyster, Daniel G. Tenen, Dietger Niederwieser, Gerhard Behre
Journal: Blood (2012)
Quality of cancer family history and referral for genetic counseling and testing among oncology practices: A pilot test of quality measures as part of the ASCO Quality Oncology Practice Initiative (QOPI).
Authors: Marie Wood, Pamela Kadlubek, Karen H. Lu, Dana Wollins, Jeffrey N. Weitzel, Michael N. Neuss, Kevin S. Hughes
Journal: Journal of Clinical Oncology (2012)

CRA1505 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
S45 Evaluating the sensitivity and specificity of active neutrophil elastase as a biomarker for bacterial infection in subjects with copd
Authors: SJ Thulborn, N Akram, V Mistry, CE Brightling, K Moffitt, D Ribeiro, M Bafadhel
Journal: Thorax (2016)

<h3>Introduction</h3> COPD is a neutrophilic disease, with the majority of subjects having a sputum neutrophil percentage of &gt;60%. Neutrophil elastase (NE) is a serine proteinase, secreted by neutrophils and macrophages during inflammation and has a role in the destruction of bacteria within the host. New advancements now allow accurate assessment of active protease levels in complex biological samples. We sought to investigate if active NE could be used as a biomarker for bacterial infection in subjects with COPD. <h3>Methods</h3> NE was quantified using ProteaseTag<sup>TM</sup> active NE Immunoassay (ProAxsis, Belfast) from cell-free sputum supernatant from 31 COPD subjects (20 Males; mean age 65, range 45 to 81) at stable state and during an exacerbation. Bacterial infection was defined as ≥10<sup>7 </sup>CFU/mL in sputum. Subject demographics, sputum cell differential counts and polymerase chain reaction (PCR) for respiratory pathogens were measured. <h3>Results</h3> Active NE was higher during an exacerbation compared to stable state (fold difference (95% CI) 0.50 (0.22 to 0.78), p = 0.001) (Figure 1). NE correlated with total sputum neutrophils (p &lt; 0.0001, r = 0.48) and total bacterial load measured by CFU/mL (p &lt; 0.01, r = 0.39) and qPCR (p &lt; 0.05, r = 0.33). When looking at the main respiratory pathogens no correlations were seen between <i>H. influenzae</i> (p = 0.43, r = −0.11), S. aureus (p = 0.34, r = −0.14) or S. pneumonia (p = 0.11, r = 0.23); however a correlation was seen between NE and <i>M. catarrhalis</i> (p = 0.01, r = 0.36). NE has an area under the receiver operator curve of 0.72 [0.58 to 0.85] to identify a bacterial infection with a sensitivity and specificity of 67.74% and 67.86% at a NE cut off of 2335ng/mL. <h3>Conclusion</h3> Active NE is elevated during a COPD exacerbation compared to baseline. Active NE is associated with neutrophilic inflammation and bacteria; and may be a viable biomarker for bacterial infection in COPD.
P50 Changing use of CT pulmonary angiography in a uk tertiary hospital over a 6-year period
Authors: R Ratnakumar, JP Corcoran, A Talwar, RJ Hallifax, I Psallidas, JM Wrightson, FV Gleeson, NM Rahman
Journal: Thorax (2016)

<h3>Background</h3> CT pulmonary angiography (CTPA) is widely regarded as the gold standard test for suspected pulmonary embolism (PE) and is increasingly used as an all-inclusive diagnostic tool for patients with symptoms of acute cardio-respiratory pathology. This has led to an increase in the number of CTPA scans, but no clear reduction in mortality from pulmonary embolic disease. CTPA may be of benefit in making other clinically significant (non-PE) diagnoses, but increased use of CTPA has resource and ionising radiation implications. <h3>Method</h3> We reviewed records of patients undergoing CTPA in our centre during the same 6-week reference period in each year from 2009 to 2014 to ascertain the number of scans positive for PE and/or other diagnoses. The clinical relevance of “other diagnoses” was evaluated, as well as whether “other diagnoses” were evident on earlier investigations such as chest X-ray. <h3>Results</h3> Patient records associated with 1882 scans were reviewed. The use of CTPA increased by two-thirds over the 6-year study period, with the likelihood of acute PE being diagnosed remaining unchanged (Table 1). Other diagnoses were seen on more than 80% of scans; the majority were either not therapeutically relevant or potentially evident from previous investigations. <h3>Conclusion</h3> Our evaluation of experience in a stable population has demonstrated increased use of CTPA scanning with no change in the diagnostic yield for acute PE. The percentage of patients with additional abnormalities has remained stable, implying the population under investigation is similar. It is uncertain if the increase in the incidence of PE is due to detection of previously undetected emboli, and whether increasing use has reduced mortality from PE. Findings also confirm significant use to screen for other causative pathology. Further work should assess the character of the emboli and the overall impact on morbidity and mortality from increasing CTPA use.
Genome-Wide Association Study for Determinants of Acute Graft Vs Host Disease (aGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation: Development of 7 SNP Model Predicting aGVHD
Authors: Eunkyung Park, Song Joo Yang, Inho Kim, Eun Hyung Jeon, Seonyang Park
Journal: Blood (2011)
P1.02-043 Multiplexed FISH (ALK/ROS1, RET, NTRK1) in Lung Adenocarcinomas: Novel Dual ALK/ROS1 Probe and Automated Scanning System
Authors: Susana Hernandez, Esther Conde, Mario Prieto, Rebeca Martinez, Margarita Rodriguez, Raquel Martin, Luis Jimenez, Luis Madrigal, Barbara Angulo, Fernando Lopez-Rios
Journal: Journal of Thoracic Oncology (2017)
Myh9 Q1443L Is a Novel Mouse Model of MYH9-Related Disorders
Authors: Nicole M Anderson, Elizabeth Berndl, Zorana Berberovic, Adili Reheman, Trecia A Brown, Monica L Bailey, Ann M Flenniken, Lucy R Osborne, S. Lee Adamson, Janet Rossant, Chen Wang, Robert F Paulson, Kelly McNagny, Mark D. Minden, Susan E Quaggin, Robert V Harrison, Heyu Ni, John D McPherson, William L. Stanford, Dwayne L Barber
Journal: Blood (2010)
OA08.07 BRAF-V600E Advanced Lung Adenocarcinoma with Leptomeningeal (LM) Disease Treated with Vemurafenib
Authors: Maria Gabriela Fernandes, José Costa, Joana Reis, Maria Jacob, Conceição Moura, José Machado, Venceslau Hespanhol
Journal: Journal of Thoracic Oncology (2017)
P3.03-008 Hypoxia-Induced Changes in microRNA Levels Contribute to Drug Resistance in a 3D Model of Malignant Pleural Mesothelioma
Authors: Yuen Yee Cheng, Yiwei Wang, Kadir Sarun, Michaela Kirschner, Laura Pellegrini, Haining Yang, David Carbone, Luciano Mutti, Nico Van Zandwijk, Ruby Lin, Glen Reid
Journal: Journal of Thoracic Oncology (2017)